drotrecogin alfa (activated)

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Severe Sepsis

Conditions

Severe Sepsis

Trial Timeline

Jan 1, 2003 → Oct 1, 2003

NCT ID

NCT00568893

About drotrecogin alfa (activated)

drotrecogin alfa (activated) is a approved stage product being developed by Eli Lilly for Severe Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00568893. Target conditions include Severe Sepsis.

What happened to similar drugs?

20 of 20 similar drugs in Severe Sepsis were approved

Approved (20) Terminated (6) Active (0)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅tacrolimusAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅CefiderocolShionogiApproved

✅Donepezil HClEisaiApproved

✅Donepezil Hydrochloride (Aricept)EisaiApproved

✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00386425	Phase 2	Completed	Nov 1, 2006	Aug 1, 2009	Severe Sepsis
NCT00279214	Approved	Completed	Nov 1, 2005	Nov 1, 2007	Sepsis
NCT00067730	Approved	Completed	Mar 1, 2003	Oct 1, 2003	Sepsis
NCT00568893	Approved	Completed	Jan 1, 2003	Oct 1, 2003	Severe Sepsis
NCT00045760	Approved	Completed	Sep 1, 2002	—	Sepsis

Competing Products

20 competing products in Severe Sepsis

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	44
CT-P17 + EU-approved Humira	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
CS-3150	Daiichi Sankyo	Phase 3	40
tacrolimus	Astellas Pharma	Approved	43
enzalutamide	Astellas Pharma	Phase 1	29
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
Alefacept	Astellas Pharma	Approved	43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	35
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	42
Cefiderocol	Shionogi	Approved	50
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
Donepezil HCl	Eisai	Approved	43
Donepezil Hydrochloride (Aricept)	Eisai	Approved	35
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40